0,1
"7.2.5.5	
Summary of evidence and recommendations for neoadjuvant and adjuvant therapy",
Recommendations,Strength rating
Do not perform cytoreductive nephrectomy (CN) in MSKCC poor-risk patients.,Strong
"Do not perform immediate CN in intermediate-risk patients who have an asymptomatic 
synchronous primary tumour and require systemic therapy.",Weak
"Start systemic therapy without CN in intermediate-risk patients who have an asymptomatic 
synchronous primary tumour and require systemic therapy.",Weak
